Program
trifarotene
Also written as “Trifarotene”, “Trifarotene Cream 0.005%” and “Trifarotene Cream”.
Its studies are mostly in Acne Vulgaris · Ichthyosis, Lamellar, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Galderma Group | 91 open or running | phase 4since Jun 25, 2020 | Jun 8, 2012 | Dec 31, 2026phase 3 · NCT07186413 |
| Sun Pharmaceutical Industries | 20 open or running | phase 1since Sep 20, 2023 | Sep 20, 2023 | none ahead |
| Mayne Pharma International Pty | 10 open or running | phase 2since Oct 24, 2018 | Oct 24, 2018 | none ahead |
| Teva Pharmaceutical Industries | 10 open or running | phase 3since Sep 19, 2022 | Sep 19, 2022 | none ahead |
Also a collaborator on its studies: teva-pharmaceuticals-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 8, 2012First study: phase 2 study in Acne VulgarisNew to Galderma GroupGalderma Group · NCT01616654 · 304 enrolled · United States
- Jul 11, 2014Phase 3 study in Acne VulgarisGalderma Group · NCT02189629 · 453 enrolled · United States, Czechia, Germany and more
- Sep 18, 2015Phase 3 study in Acne VulgarisGalderma Group · NCT02556788 · 1,212 enrolled · United States, Czechia, Hungary and more
- Oct 1, 2015Phase 3 study in Acne VulgarisGalderma Group · NCT02566369 · 1,208 enrolled · United States, Canada, Germany and more
- Oct 24, 2018Mayne Pharma International Pty's first study: phase 2 study in Ichthyosis, LamellarNew to Mayne Pharma International PtyMayne Pharma International Pty · NCT03738800 · 65 enrolled · United States, Australia, Canada and more
- Apr 12, 2019Phase 3 study in Acne VulgarisGalderma Group · NCT03915860 · 47 enrolled · United States
- Jun 25, 2020Phase 4 study in Acne VulgarisGalderma Group · NCT04451330 · 202 enrolled · United States, Puerto Rico
- Apr 20, 2021Phase 4 study in Acne VulgarisGalderma Group · NCT04856904 · 121 enrolled · United States, Canada, France
- Oct 11, 2021Phase 4 study in Acne VulgarisGalderma Group · NCT05089708 · 123 enrolled · United States, Spain
- Sep 19, 2022Teva Pharmaceutical Industries's first study: phase 3 study in Acne VulgarisNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT05550337 · 807 enrolled · United States
- Sep 20, 2023Sun Pharmaceutical Industries's first study: phase 1 study in Acne VulgarisNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT06063473 · 762 enrolled · United States
- Dec 10, 2024Phase 1 study in Acne VulgarisSun Pharmaceutical Industries · NCT06733402 · 1,000 enrolled · United States
- Aug 26, 2025Phase 3 study in Acne VulgarisGalderma Group · NCT07186413 · 561 enrolled · China
Ahead
- Dec 31, 2026Primary completion: phase 3 study in Acne VulgarisGalderma Group · NCT07186413
TargetBeta
“Retinoic acid receptor gamma agonist”ChEMBL 37, by rule
Other programs on RARG
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Palovarotenerule | Ipsen | phase 3 | 10 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07186413Acne Vulgaris · China | 3 | Active, not recruiting | Galderma Group | Dec 31, 2026 | 561 |
| NCT06733402Acne Vulgaris · United States | 1 | Completed | Sun Pharmaceutical Industries | Jun 20, 2024 | 1,000 |
| NCT06063473Acne Vulgaris · United States | 1 | Completed | Sun Pharmaceutical Industries | Jul 13, 2023 | 762 |
| NCT05550337Acne Vulgaris · United States | 3 | Completed | Teva Pharmaceutical Industries | May 9, 2023 | 807 |
| NCT05089708Acne Vulgaris · United States, Spain | 4 | Completed | Galderma Group | Dec 15, 2022 | 123 |
| NCT04856904Acne Vulgaris · United States, Canada, France | 4 | Completed | Galderma Group | Feb 8, 2023 | 121 |
| NCT04451330Acne Vulgaris · United States, Puerto Rico | 4 | Completed | Galderma Group | Apr 26, 2021 | 202 |
| NCT03915860Acne Vulgaris · United States | 3 | Completed | Galderma Group | Dec 23, 2019 | 47 |
| NCT03738800Ichthyosis, Lamellar · United States, Australia, Canada and more | 2 | Terminated | Mayne Pharma International Pty | Sep 3, 2021 | 65 |
| NCT02566369Acne Vulgaris · United States, Canada, Germany and more | 3 | Completed | Galderma Group | Nov 14, 2017 | 1,208 |
| NCT02556788Acne Vulgaris · United States, Czechia, Hungary and more | 3 | Completed | Galderma Group | Feb 7, 2017 | 1,212 |
| NCT02189629Acne Vulgaris · United States, Czechia, Germany and more | 3 | Completed | Galderma Group | Feb 23, 2017 | 453 |
| NCT01616654Acne Vulgaris · United States | 2 | Completed | Galderma Group | Jul 24, 2013 | 304 |
How it is read
Names in the registry
- “Trifarotene”, 2 entries
- “Trifarotene Cream 0.005%”, 2 entries
- “Trifarotene Cream”, 2 entries
- “Trifarotene 0.005 % Topical Cream”, 1 entry
- “CD5789 Cream 200 µg/g”, 1 entry
Conditions, from the studies’ own filings
- Acne Vulgaris, 12 studies
- Ichthyosis, Lamellar, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.